Renal Evaluation in Women with Preeclampsia by Facca, T.A. et al.
125
    © 2012 S. Karger AG, Basel
 Original  Paper 
  Nephron Extra 2012;2:125–132
  Renal Evaluation in Women with 
Preeclampsia
    T.A. Facca    G. Mastroianni Kirsztajn    A.R. Pereira    S.R. Moreira    
V.P.C. Teixeira    S.K. Nishida    N. Sass 
    Disciplines of Obstetrics and Nephrology of the Federal University of São Paulo (UNIFESP), 
 São  Paulo ,  Brazil
  
 
 Key  Words
  A l b u m i n u r i a        Podocytes       Preeclampsia       Proteinuria       Retinol-binding proteins
  A b s t r a c t
   Background/Aims:  Preeclampsia (PE) is a cause of glomerulopathy worldwide. Urinary retinol-
binding protein (RBP) is a marker of proximal tubular dysfunction, albuminuria is an endothe-
lial injury marker, urine protein:creatinine ratio (PCR) may have a predictive value for renal dis-
ease later in life, and, recently, podocyturia has been proposed as a sensitive tool in pregnancy, 
but it needs to be tested. The aim of this study was to evaluate renal involvement in PE and 
healthy pregnancy.   Methods:  Case-control study with 39 pregnant women assessed after 20 
weeks of gestation (25 in the control group, CG, and 14 in the PE group) by performing urinary 
tests.  Results:  Mean ( 8  SD) age and gestational age of the CG were 26.9  8   6.4 years and 37.1  8   
5.0 weeks, and of the PE group 26.4   8   6.9 years and 30.6   8   5.6 weeks, respectively (p = 0.001). 
Mean ( 8  SD) urinary RBP (p = 0.017), albuminuria (p = 0.002), and urinary albumin concentration 
(UAC) ratio (p = 0.006) of the CG were 0.4   8   0.7 mg/l, 7.3   8   6.9 mg/l, and 8.2   8   6.7 mg/g and 
of the PE group 2.0   8   4.4 mg/l, 2,267.4   8   2,130.8 mg/l (p = 0.002), and 3,778.9   8   4,296.6 mg/g 
(p = 0.006), respectively. Mean (  8  SD) urine PCR in the PE group was 6.7   8   6.1 g/g (p   !   0.001). 
No statistical differences were found between podocyturia in the CG and PE group (p = 0.258). 
  Conclusions:  Urinary RBP, PCR, albuminuria, and UAC ratio were elevated in the PE group in 
comparison to the CG. Podocyturia did not predict PE.     Copyright © 2012 S. Karger AG, Basel
  Published online: May 22, 2012 
EXTRA
  Thaís Alquezar Facca
This is an Open Access article licensed under the terms of the Creative Commons Attribution- 
NonCommercial-NoDerivs 3.0 License (www.karger.com/OA-license), applicable to the online 
version of the article only. Distribution for non-commercial purposes only.
    Federal University of São Paulo (UNIFESP)
    Napoleao de Barros Street, 875 Clementino Villa
    São Paulo, SP 04024-002 (Brazil)
    Tel. +55 11 5571 0761, E-Mail tafacca    @    hotmail.com 
 www.karger.com/nne 
  DOI:  10.1159/000338271 126
Nephron Extra 2012;2:125–132
 DOI:  10.1159/000338271 
  Published online: May 22, 2012  
EXTRA
  Facca et al.: Renal Evaluation in Women with Preeclampsia 
www.karger.com/nne
    © 2012 S. Karger AG, Basel
  Introduction
    Preeclampsia (PE) occurs in 3–10% of all pregnancies   [1, 2]   and is a major cause of ma-
ternal and fetal morbidity and mortality   [3, 4]  . It is a multisystem disease exclusive to preg-
nancy and is defined as hypertension (  6  140/90 mm Hg) and proteinuria (  6  300 mg/24 h or 
  6  1 + in dipstick urinalysis) after 20 weeks of gestation. It can persist until 12 weeks after 
labor.
    Hypertension in pregnancy can be manifest in different clinical forms: gestational hy-
pertension, PE, eclampsia, or gestational hypertension and preeclampsia superimposed with 
chronic hypertension   [5, 6]  .
    PE is associated with many serious complications during pregnancy. These are eclamp-
sia, brain edema, stroke, posterior reversible encephalopathy syndrome, and HELLP syn-
drome (hemolysis, elevated liver enzymes, and low platelet count)   [7]  . Moreover, PE may be 
related to future increased cardiovascular risk   [8]   and also renal disease   [9]  .
  Cardiovascular disease (CVD) and PE apparently have similar pathophysiological mech-
anisms as both are associated with endothelial dysfunction, metabolic syndrome, oxidative 
stress, and share some similar risk factors such as obesity, smoking, advanced age, renal dis-
ease, and diabetes  [10] . The exact relationship between PE and CVD has not been elucidated; 
the metabolic stress triggered by PE probably induces vascular injury that contributes to the 
onset of CVD   [11]   and even the future risk of chronic kidney disease (CKD)   [12]  .
    Despite extensive study of PE, its etiopathogenesis has not been totally elucidated. Pos-
sible mechanisms of PE include inadequate placentation leading to an inadequate uteropla-
cental perfusion with subsequent tissue hypoxia and oxidative stress, triggering the release 
of antiangiogenic factors in the maternal circulation causing a systemic inflammatory reac-
tion. Further, these factors trigger generalized endothelial dysfunction which is responsible 
for the hypertensive syndrome   [13, 14]  .
    Endothelial dysfunction in PE occurs because of the imbalance of its homeostasis. Pro-
angiogenic factors such as PlGF (placental growth factor) and VEGF (vascular endothelial 
growth factor) are inhibited by the action of other factors probably originated by the hypox-
ia of the cytotrophoblast. The main anti-angiogenic factors are sEng (soluble endoglin) and 
sFlt-1 (soluble vascular endothelial growth factor)   [15–18]  .
    VEGF plays also an important role in glomerular filtration as a protective factor against 
structural podocyte damage allowing its proper function in the endothelium   [19, 20]  . Harm 
to the podocyte is directly related to the renal involvement in PE   [21]  , as injury leads to the 
loss of its interdigitation, a dedifferentiation process, and deficient adhesion to the glomeru-
lar basement membrane with consequent urinary podocyte excretion and development of 
glomerulosclerosis   [22]  .
    Proteinuria is probably the main cause of progression of renal disease in PE   [23]  , and its 
level is directly related to a poor maternal and perinatal outcome   [24]  . Microalbuminuria is 
a renal endothelial injury marker resulting from systemic or renal vascular damage, is asso-
ciated with increased cardiovascular risk especially in hypertensive and diabetic individuals, 
and is one of the main tests for screening CKD   [25]  . Thus, persistent microalbuminuria or 
proteinuria after PE may represent a greater risk for CVD and CKD   [26]  .
    The complications of PE can be prevented if detected early. Diagnosis of renal disorders 
after PE may allow prompt initiation of treatment. Early renal screening is essential to im-
prove long-term outcome and reduce the pregnancy risks. This study was designed to better 
understand this disorder and its tubular and glomerular repercussions by evaluating urinary 
markers in PE and a control group (CG).127
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  Materials  and  Methods
  This was a case-control study with a total of 39 pregnant women after 20 weeks of gesta-
tion, 25 in the CG and 14 in the PE group, assessed by renal parameters such as podocyturia, 
proteinuria, albuminuria, urinary albumin concentration (UAC) ratio, urinary retinol-bind-
ing protein (RBP), and urine protein:creatinine ratio (PCR). This study was approved by the 
Ethics Committee of the Federal University of São Paulo (UNIFESP).
    The study population consisted of women from maternity hospitals located in the met-
ropolitan region of São Paulo who were hospitalized because of PE, and the CG included 
corresponding healthy pregnant women who also attended those hospitals.
    The PE group was composed of women diagnosed according to the research definition 
criteria established by the National High Blood Pressure Education Program (NHBPEP, 
1990)  [5] . The CG were healthy pregnant women with no history of hypertension at any time 
of life. To define the HELLP syndrome, we used the criteria of Sibai, 1990   [27]  : hemolysis 
(abnormal peripheral smear, total bilirubin   1  1.2 mg/dl and/or lactate dehydrogenase   1  600 
IU/l), elevated liver enzymes (glutamic oxaloacetic transaminase, glutamic pyruvic trans-
aminase   1  70 IU/l), and thrombocytopenia (platelets   !  100,000/mm  3 ).
  The following parameters were assessed in all selected women: age (years), gestational age 
(weeks), body mass index (BMI; kg/m  2 ) pre-pregnancy and in the current pregnancy, urine 
PCR, random protein (g/l) creatinine (g/l) ratio, urinary RBP (mg/l), albuminuria (mg/l), 
UAC ratio (mg/g), urinary total cell number, podocyturia, and podocyte/total cells ratio (%).
    We excluded patients with multiple pregnancy, diabetes mellitus, previously diagnosed 
kidney disease, autoimmune diseases, current urinary tract infection, previously detected 
microalbuminuria, and a history of hypertension or proteinuria.
  All patients were given an explanation about this study and signed the informed consent 
form.
    Urine samples were collected and frozen at –20    °    C. All samples were sent to the labora-
tory of the Kidney and Hypertension Hospital, UNIFESP, for analysis of albuminuria, ran-
dom proteinuria, urine PCR, urinary RBP, and UAC ratio. Albuminuria and proteinuria were 
evaluated by immunoturbidimetric method, the urinary RBP by enzyme immunoassay using 
monoclonal antibodies, and urine creatinine by the alkaline picrate colorimetric method.
  Microalbuminuria in random urine samples was considered positive for values between 
30 and 300 mg/l, and macroalbuminuria was defined above this level   [28]  . Urinary RBP was 
elevated when   1  0.4 mg/l   [29]  . The cutoff adopted for urine PCR was 0.14   [30]  . The cutoff for 
UAC ratio was 30 mg/g   [31]  .
  P o d o c y t u r i a
    Podocytes were detected in random urine samples (6 ml) fixed with absolute ethyl alco-
hol 99.5% (1:    1) and stored at 4    °    C. The urine sample was centrifuged for 10 min at 1,000 r.p.m. 
in the centrifuge LS-3 plus (Celm, Brazil) and cytocentrifuged in the CT-12 (Presvac, Brazil) 
for 5 min at 500 r.p.m. at room temperature, and then frozen at –20    °    C. The slide was fixed 
for 10 min at room temperature with formaldehyde 2%, and then washed for 5 min with PBS 
(phosphate-buffered saline). The slide was incubated with 0.3% Triton for 10 min at room 
temperature and washed for 5 min in PBS. The slide was incubated for 60 min with blocking 
solution consisting of PBS with BSA (bovine serum albumin) 0.2%, NH  4 Cl 50 m  M,  and goat 
serum 1% at room temperature followed by rabbit IgG anti-nephrin polyclonal antibody 
H-300 sc-28192 (Santa Cruz Biotechnology, USA) dilution 1:    50 in PBS and BSA overnight at 
4    °    C and washed for 10 min with PBS. The slide was incubated for 45 min at room tempera-
ture with fluorescein (FITC) anti-rabbit IgG secondary antibody (Santa Cruz Biotechnology) 
dilution 1:    100 in PBS and BSA. Then Vectashield (mounting medium for fluorescence) with 128
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DAPI (4   6-diamino-2-phenylindole dihydrochloride) was applied (H-1200 Vector Laborato-
ries, Inc., USA). 
    The detection of podocytes was performed by an experienced observer, who was blind-
ed to which group the slide belonged, by immunofluorescence techniques as shown in  figure 
1  . The podocytes and the total number of cells were counted in 15 fields photographed un-
der 400  !   magnification with a digital camera coupled to an epifluorescence microscope 
DM1000 (Leica, Germany) connected to a computer. The results were expressed as podocyte/
total cells (%) per area of higher cell concentration (hot spots) in the field of 400  !   detected 
by the positive nuclear and cytoplasmic staining.
  S t a t i s t i c s
    The calculation of mean, median, minimum, maximum, and standard deviation was 
performed for quantitative variables. The qualitative variables were analyzed by calculating 
the absolute and relative frequency (percentage). The statistical analysis between the CG and 
PE group according to race, parity, history of PE, BMI classification, smoking, and protein-
uria (dipstick urinalysis) was performed using     2  test, Fisher’s exact test or its extension. The 
Student’s t test was used for independent samples such as age, BMI, albuminuria, UAC ratio, 
and the number of total cells. The Mann-Whitney U test was used for gestational age, urine 
PCR, random proteinuria, urinary RBP, podocyte cells, and podocyte/total cells ratio. Point 
estimation and interval of sensitivity, specificity, and area under the ROC curve were used 
to obtain the cutoff points for urine PCR and UAC ratio, with the goal of predicting PE. Point 
estimation and interval of the Pearson correlation coefficient between 24-hour proteinuria 
and podocyte/total cells ratio in PE was calculated. For all the results obtained through the 
analysis we used a significance level of      = 5%. Data were entered into Excel spreadsheets for 
Windows 2010. Statistical analysis was performed with the R-software version 2.11.0. 
  R e s u l t s
    The sample selected for this study consisted of 39 women, 35.9% (14/39) with PE and 
64.1% (25/39) without PE. All control subjects were negative for proteinuria (dipstick uri-
nalysis) and none of the subjects in the PE group had negative results for proteinuria by dip-
  Fi g .   1.   P o d o c y t u r i a  i n  P E  b y
immunofluorescence techniques 
using rabbit IgG anti-nephrin 
polyclonal antibody. Positive nu-
cleus (blue staining); positive cy-
toplasm (green staining). Pari-
etal epithelia cell (high cyto-
plasm/nucleus ratio); podocyte 
cell (low cytoplasm/nucleus ra-
tio). 129
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stick urinalysis. A comparison of the baseline data for age, ethnicity, primiparity, previous 
pregnancy history, BMI, and gestational age is given in   table 1  .
    The total number of cells in the urine in the CG was 346.1   8   327.2 cells/hot spots and 
in the PE group 467.9   8   549.1 cells/hotspots (p = 0389). For podocyturia, the mean total 
number of podocytes in the CG was 0.9   8   1.6 and in the PE group 9.3   8   16.8 (p = 0.212). 
Also, in the CG we found 0.5   8   0.8 podocytes/total number of cells (%) and in the PE group 
1.2   8   1.7 (p = 0.258). 
    Urine PCR and random proteinuria were both 0.0   8   0.0 in the CG, and in the PE group 
6.7   8   6.1 g/g (p   !   0.001) and 4.4   8   4.3 g/l (p   !   0.001), respectively. Also statistically signif-
icant were: urinary RBP, which was 0.4   8   0.7 mg/l in the CG and 2.0   8   4.4 mg/l in the PE 
group (p = 0.017), albuminuria, which was 7.3   8   6.9 mg/l in the CG and 2,267.4   8   2,130.8 
mg/l in the PE group (p = 0.002), and UAC ratio, which was 8.2   8   6.7 mg/g in the CG and 
3,778.9   8   4,296.6 mg/g in the PE group (p = 0.006).
  Twenty-four-hour proteinuria as well as the following blood tests were collected only for 
women in the PE group: hemoglobin, platelets, LDH, AST, ALT, urea, and serum creatinine. 
The PE group was investigated for 24-hour proteinuria, but only 9 of 14 (64.2%) individuals 
in this group completed this evaluation because of inadequate volume collection or interrup-
tion by labor.
    There seems to be no relationship between levels of 24-hour proteinuria and podocytes/
total cells ratio. This was confirmed by the estimates of Pearson’s correlation coefficients 
(0.0188; 95% CI –0.593 to 0.725). Because of the small sample size (only 9 pregnant women), 
the interval estimate of the correlation coefficient is inaccurate.
    As shown in the comparison of these markers between the CG and the PE group, urine 
PCR and UAC ratio are good predictors of PE. The same observations were not possible 
based on the podocyte/total cells ratio due to low values of sensitivity and specificity.
  Discussion
  Our study demonstrated that women with PE had higher urinary RBP in comparison to 
the CG. We also found elevated levels of albuminuria and total proteinuria. All patients with 
PE had increased urine PCR and UAC ratio.
    RBP is a novel adipokine mainly synthesized by the liver which is strongly associated 
with inflammation, obesity, and insulin resistance. RBP4 is a plasma protein that seems to 
have no correlation with maternal age, gestational age, pre-pregnancy BMI, and neonatal 
birth weight. It is decreased in acute stress conditions, such as pyelonephritis   [32]  , though it 
  Table  1.    Demographic data
 Control  group   PE  group  p 
 Patients,  n  25  14  – 
 Age,  years  26.986.4 26.486.9  0.799 
  Caucasian ethnicity    11/25 (44.0%)  9/14 (64.3%)  0.224 
 Primiparous   10/25  (40.0%)   10/14  (71.4%)  0.060 
  Past history of PE  1/25 (4.0%)  3/14 (21.4%)  0.123 
  Smokers  3/25 (12.0%)  2/14 (14.3%)    >0.999 
  Normal BMI pre-pregnancy    17/29 (68.0%)  8/14 (57.1%)  0.41 
  Normal BMI current pregnancy    13/25 (52.0%)  3/14 (21.4%)  0.237 
  Gestational age, weeks  37.185.0 30.685.6  0.001 
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is elevated in PE in comparison to normal pregnancy, specifically in early-onset PE   [33]  . 
RBP4 and insulin resistance index are both higher in overweight pregnant women with late-
onset PE when compared with a CG, which suggests that RBP might act in the pathophysiol-
ogy of vascular dysfunction in PE   [34]  .
    Excretion of RBP increases during pregnancy, and it is especially higher in the second 
and third trimesters than in the first   [35]  ; however, RBP4 remains within normal levels   [36]  . 
There are no studies evaluating urinary RBP in PE; we reported the possibility of decreased 
tubular reabsorption in this disorder, although further research is needed to confirm it.
    Another marker for the detection of proteinuria is the urine PCR, which corrects the 
proteinuria level by urinary excretion of creatinine and is helpful in the follow-up and treat-
ment of proteinuric nephropathies. The evaluation of urine PCR has conflicting reports and 
its cutoff value has no uniform recommendation yet, though it could be a reasonable alterna-
tive to the 24-hour urine in pregnant women for diagnosing PE, avoiding the influence of 
variation in urinary solute concentration, and also a more convenient and rapid method  [37] , 
especially in severe PE   [38]  . Moreover, urine PCR may be a better screening test than the au-
tomatic dipstick urinalysis   [39]  .
    Urinary excretion of albumin is a risk factor for CVD and CKD, and it might indicate 
renal damage; hence, it is useful for monitoring patients with nephropathies   [40]  .
    Microalbuminuria is a known risk factor for vascular disease, and PE is associated with its 
high occurrence  [41] . Pre-pregnancy microalbuminuria in type 1 diabetic women is also related 
to an increased risk of PE   [42]   and preterm delivery   [43]  . Either in PE or in diabetes, the meta-
bolic control and the follow-up of microalbuminuria may improve pregnancy outcome   [44]  .
    Podocyte cells excreted in the urine are found in the presence of several kidney disorders 
and, although further studies are still needed, they might be used to differentiate PE from 
other glomerular disorders that involve hypertension and proteinuria after 20 weeks of gesta-
tion  [2] . Recently, a study  [21]  raised the hypothesis that podocyturia may be present at the time 
of clinical diagnosis of PE and it may also be correlated with proteinuria as the excretion of 
these cells appears to be present in the acute phase of renal diseases. In our study, we did not 
find a significant difference between podocyturia in the CG and PE group, but we detected 3 
cases in the PE group with about 4-fold the podocyturia of any other patient. It is possible that 
the renal lesion in these women was more intense, and they might have a future risk of CKD.
  PE is an important cause of glomerulopathy worldwide  [45] , which might be an important 
clinical marker for increased risk of subsequent end-stage renal disease   [46]  . Renal filtration 
and function are affected in PE   [47, 48]   and might not completely recover immediately post-
partum   [49]  . The early diagnosis of a glomerular disorder after PE supported by laboratory 
tests may provide prompt initiation of treatment and improve long-term outcome.
    In summary, urinary RBP, urine PCR, albuminuria, and UAC ratio were elevated in the 
PE group in comparison to the CG. Considering the limitations of our sample size, podocytu-
ria was not found to be a good predictor of PE, although it might be associated with glomeru-
lar lesions after PE. These findings suggest that renal evaluation may add important informa-
tion to the follow-up of glomerular injury in women whose pregnancy was complicated by PE. 
More studies are needed for a better understanding of the mechanisms involved in PE and its 
systemic repercussions and, beyond that, to elucidate the relationship between these disorders.
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